Do we have to withdraw antiandrogenic therapy in prostate cancer patients before PET/CT with [11C]choline?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Effect of Androgen Deprivation Therapy on the Results of PET/CT with 18F-Fluciclovine in Patients with Metastatic Prostate Cancer.Tomography (Ann Arbor, Mich.) · 2022
   Article
2. Diagnostic performance ofAmerican journal of nuclear medicine and molecular imaging · 2021
   Article
3. The relationship between local recurrences and distant metastases in prostate cancer: canEuropean journal of nuclear medicine and molecular imaging · 2018
   Article
4. The use of PET/CT in prostate cancer.Prostate cancer and prostatic diseases · 2018
   Review
5. PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.European journal of nuclear medicine and molecular imaging · 2017
   Review
6. Effect of androgen deprivation therapy on intraprostatic tumour volume identified onThe British journal of radiology · 2017
   Article
7. Prostate-specific antigen and prostate-specific antigen velocity as threshold indicators in 11C-acetate PET/CTAC scanning for prostate cancer recurrence.Clinical nuclear medicine · 2014
   Article
8. Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy?European journal of nuclear medicine and molecular imaging · 2014
   Article
9. Functional imaging for prostate cancer: therapeutic implications.Seminars in nuclear medicine · 2012
   Review

Corrections and comments

• Comment on
  Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study.2011

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as